Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Neven

Showing results (281-290 of 383) with videos related to

Pageof 39
Sort By:
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 10, 2024
Stromal Tumor-Infiltrating Lymphocytes in Hormone Receptor-Positive/HER2 Negative Metastatic Breast CancerAnirudh Pabba, Gitte Zels, Maxim De Schepper, et al.
European Journal of Cancer (Oxford, England : 1990)|May 20, 2022
Outcome of breast cancer patients treated with chemotherapy during pregnancy compared with non-pregnant controlsFrédéric Amant, Valentina Nekljudova, Charlotte Maggen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 9, 2016
Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor-Positive Metastatic Breast CancerWeimin Li, Joyce O'Shaughnessy, Daniel Hayes, et al.
Cancer|March 19, 2013
Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trialHoward A Burris, Fabienne Lebrun, Hope S Rugo, et al.
NPJ Breast Cancer|April 27, 2026
Imlunestrant with or without abemaciclib in advanced breast cancer: safety analyses from the EMBER-3 trialJoyce O'Shaughnessy, Francois-Clement Bidard, Patrick Neven, et al.
Therapeutic Advances in Medical Oncology|February 9, 2023
Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-, node-positive, high-risk early breast cancerShani Paluch-Shimon, Patrick Neven, Jens Huober, et al.
Breast Cancer Research and Treatment|July 6, 2012
A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancerMartin Schuler, Ahmad Awada, Philipp Harter, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|August 5, 2025
Corrigendum to "Histopathological Insights into Metastatic Breast Cancer Gained From Rapid Autopsies" [Laboratory Investigation 105(2025) 104202]Gitte Zels, Anirudh Pabba, Maxim De Schepper, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|May 31, 2025
Histopathological Insights into Metastatic Breast Cancer Gained From Rapid AutopsiesGitte Zels, Anirudh Pabba, Maxim De Schepper, et al.
Breast Cancer Research and Treatment|July 17, 2008
Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptorsOlivier Brouckaert, Saskia Pintens, Vanya Van Belle, et al.
Pageof 39

Showing results (281-290 of 383) with videos related to

Sort By:
Pageof 39
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 10, 2024
Stromal Tumor-Infiltrating Lymphocytes in Hormone Receptor-Positive/HER2 Negative Metastatic Breast CancerAnirudh Pabba, Gitte Zels, Maxim De Schepper, et al.
European Journal of Cancer (Oxford, England : 1990)|May 20, 2022
Outcome of breast cancer patients treated with chemotherapy during pregnancy compared with non-pregnant controlsFrédéric Amant, Valentina Nekljudova, Charlotte Maggen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 9, 2016
Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor-Positive Metastatic Breast CancerWeimin Li, Joyce O'Shaughnessy, Daniel Hayes, et al.
Cancer|March 19, 2013
Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trialHoward A Burris, Fabienne Lebrun, Hope S Rugo, et al.
NPJ Breast Cancer|April 27, 2026
Imlunestrant with or without abemaciclib in advanced breast cancer: safety analyses from the EMBER-3 trialJoyce O'Shaughnessy, Francois-Clement Bidard, Patrick Neven, et al.
Therapeutic Advances in Medical Oncology|February 9, 2023
Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-, node-positive, high-risk early breast cancerShani Paluch-Shimon, Patrick Neven, Jens Huober, et al.
Breast Cancer Research and Treatment|July 6, 2012
A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancerMartin Schuler, Ahmad Awada, Philipp Harter, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|August 5, 2025
Corrigendum to "Histopathological Insights into Metastatic Breast Cancer Gained From Rapid Autopsies" [Laboratory Investigation 105(2025) 104202]Gitte Zels, Anirudh Pabba, Maxim De Schepper, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|May 31, 2025
Histopathological Insights into Metastatic Breast Cancer Gained From Rapid AutopsiesGitte Zels, Anirudh Pabba, Maxim De Schepper, et al.
Breast Cancer Research and Treatment|July 17, 2008
Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptorsOlivier Brouckaert, Saskia Pintens, Vanya Van Belle, et al.
Pageof 39